Invesco PHLX Semiconductor ETF (NASDAQ: SOXQ)

에 대한 최신 뉴스 Invesco PHLX Semiconductor ETF (NASDAQ:SOXQ)

Technology

Real Estate

Other

The Fund generally will invest at least 90% of its total assets in the securities that comprise the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq, Inc. (Nasdaq or the Index Provider) compiles the Underlying Index, which is a modified market-capitalization weighted index designed to measure the performance of the 30 largest companies listed in the United States that are engaged in the semiconductor business, as determined by the Index Provider.

NVIDIA Corporation

Broadcom Inc

Advanced Micro Devices Inc

Texas Instruments Inc

Taiwan Semiconductor Manufacturing Co. Ltd. - Adr

Kla Corp

Intel Corp.

Analog Devices, Inc.

Asml Holding Nv

Lam Research Corp

Marvell Technology Inc

Qualcomm Inc

Applied Materials Inc

Intel Corp

MICRON TECHNOLOGY INC

Invesco PHLX Semiconductor ETF

biden china shutter

Asia

Government

Large Cap

Regulations

Sector ETFs

Global

Tech

ETFs

AOTG

ESPO

FEPI

NVDA

EA Series Trust Strive U.S. Semiconductor ETF

SHOC

SMHX

SOXQ

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

SOXY

워싱턴이 우호적이지 않은 국가들에 대한 반도체 칩 수출 규제를 강화함에 따라 엔비디아(NASDAQ:NVDA)와 어드밴스드 마이크로 디바이시스(NASDAQ:AMD)는 반도체 산업의 글로벌 환경을 혼란에 빠뜨릴 수 있는 지정학적 권력 이동의 한가운데에 있다.

AI 시장을 뒤흔들 바이든의 최종 칩 규제: 엔비디아, AMD에 높은 지분을 가진 10개 ETF

arm-qualcomm-shutter

Legal

QCOM

SEMI

SOXL

세계 최대 칩 제조사 중 두 곳인 ARM 홀딩스(NASDAQ:ARM)와 퀄컴(NASDAQ:QCOM)이 이번 주에 지적재산권에 대한 의견 차이로 법정에서 충돌할 예정이다. 

ARM 홀딩스 vs 퀄컴, 칩 설계 저작권 재판 시작

Semiconductor.Shutterstock

Equities

Mid Cap

Broad U.S. Equity ETFs

AAPL

ACLS

AVGO

MSFT

NVMI

OLED

QRVO

인공 지능의 추진에 힘입어 반도체 기업들의 주가가 고공행진을 이어가고 있는 가운데, 현재 미국 칩 제조 산업은 총 가치가 6조 3천억 달러에 달한다. Invesco PHLX 반도체 ETF(NYSE:SOXQ)가 반영하는 필라델피아 반도체 지수(PHLX Semiconductor Sector Index)는 이번 주에 6% 상승할 것으로 예상되어 두 달 만에 가장 강력한 실적을 기록하고 사상 최고 수준을 달성했다.

반도체 업계가 $6조 3천억에 도달, 사상 최고 기록: 이번 주 엔비디아를 앞선 5개의 칩 주식

Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock is trading higher on Wednesday.
As per data from Benzinga Pro, session volume stands at 31.74 million versus an <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">average volume of 674.72k</a>.
What Happened: The medical device and pharmaceutical packaging company initiated shipments for previously announced purchase orders across <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45766676/sharps-technology-begins-shipments-across-three-customer-orders-under-previously-announced-purchas" rel="noreferrer noopener">three customer orders</a>.
These shipments mark the company&#8217;s first deliveries of its SecureGard and SoloGard product lines and its transition to generating commercial revenue.
&#8220;These initial shipments mark a key operational milestone as Sharps officially transitions to a commercial-stage company,&#8221; stated Robert Hayes, CEO of Sharps Technology.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39647243/whats-going-on-with-nano-cap-medical-device-focused-sharps-technology-on-friday" rel="noreferrer noopener">What&#8217;s Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday?</a>
<h1 class="wp-block-heading">SoloGard Shipment</h1>
Sharps has initiated shipment of its first commercial order of SoloGard under a previously announced $50 million supply agreement with a U.S.-based leader in <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">IV flushing solutions</a>.
The delivery includes customized 10ml SoloGard smart safety syringes manufactured at the company&#8217;s upgraded facility in Hungary.
SoloGard is a smart safety syringe featuring ultra-low waste design, standard luer lock compatibility and re-use prevention technology.
This inaugural $400,000 purchase order marks the beginning of a five-year contract to supply up to 500 million syringes and represents the first revenue-generating shipment under the strategic supply agreement.
SoloGard&#8217;s manufacturing is supported by advanced molding and automation technologies recently invested in by the company, enabling Sharps to meet the anticipated increase in demand under the agreement during the second half of 2025.
<h1 class="wp-block-heading">SecureGard Shipment</h1>
Sharps delivered SecureGard smart safety syringes in a separate shipment to a Hungarian vaccine provider following a $100,000 purchase order.
SecureGard is a safety syringe featuring an integrated active recessed safety system, ultra-low waste design and re-use prevention technology.
Combined with the SoloGard order, total purchase commitments reached approximately $500,000, establishing Sharps as a revenue-producing company and supporting its transition to commercial operations.
<h1 class="wp-block-heading">Additional Shipment</h1>
Additionally, Sharps has commenced shipment of 200,000 units of 1ml low-dead space syringes to a Swiss-based global provider of cosmetic, dental and ophthalmic injectable therapies.
The syringes will be used in a specialized injection pen to deliver Botox and represent the first tranche of a 1-million-unit order.
STSS Price Action: STSS stock is up 60.60% at $6.01 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45770679/alibaba-jd-see-sales-soar-in-618-festival-apple-and-xiaomi-emerge-as-top-selling-brands" target="_blank" rel="noreferrer noopener">Alibaba, JD See Sales Soar In 618 Festival, Apple And Xiaomi Emerge As Top Selling Brands</a></li>
</ul>
Photo: solarseven via Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

STSS

Why Is Sharps Technology Stock Soaring On Wednesday?

Cellectar Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock is trading higher on Wednesday.
As per data from Benzinga Pro, session volume stands at 361.96 million versus an <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">average volume of 968.03k</a>.
What Happened: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on Wednesday for the company&#8217;s iopofosine I 131, a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for relapsed/refractory Waldenstrom <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">macroglobulinemia (r/r WM)</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/12/42442003/cellectar-biosciences-stock-plunges-as-cancer-focused-cancer-firm-pursues-strategic-options" target="_blank" rel="noreferrer noopener">Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options</a>
Why It Matters: WM is the dominant subtype of lymphoplasmacytic lymphoma.
Data from the Phase 2 CLOVER WaM study, including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2%, which exceeded the agreed-upon primary endpoint of a 20% MRR, were presented during the 66th Annual American Society of Hematology Conference in December 2024.
As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45768008/cellectar-granted-u-s-fda-breakthrough-therapy-designation-for-iopofosine-i-131-in-waldenstrom-mac" rel="noreferrer noopener">and Orphan Drug Designation</a>.
The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I&nbsp;131 for r/r WM and PRIME Designation for WM.
What&#8217;s Next: Separately, the company has provided the EMA with a data package that includes extensive supportive preclinical, regulatory, and manufacturing data and safety and efficacy data from the CLOVER WaM Phase 2b clinical trial.
The EMA will review the package to determine whether there is enough clinical evidence to address the required criteria for Cellectar to apply for a fast-track, conditional marketing authorization approval.
In late July 2025, the company expects a recommendation from the EMA on whether Cellectar should file a Medical Authorization Application.
Price Action: CLRB stock is trading higher by 57.9% to $0.43 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/small-cap/25/06/45770622/sprinklr-rises-on-solid-earnings-raised-outlook-and-new-150-million-buyback-plan" target="_blank" rel="noreferrer noopener">Sprinklr Rises On Solid Earnings, Raised Outlook, And New $150 Million Buyback Plan</a></li>
</ul>
Photo by Tada Images via Shutterstock

News

CLRB

What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained

WIIM

ONEOK shares are trading lower after the company acquired the remaining shares of Basin JV for $940 million. Additionally, Barclays cut its price target on the stock from $101 to $91.

<a href="https://www.bloomberg.com/news/articles/2025-06-04/trump-tariffs-carney-holds-back-on-retaliation-says-us-talks-are-progressing">https://www.bloomberg.com/news/articles/2025-06-04/trump-tariffs-carney-holds-back-on-retaliation-says-us-talks-are-progressing</a>

'Carney Holds Back on Tariff Retaliation, Says US-Canada Talks Are Progressing'- Bloomberg

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 5.23% on an annualized basis producing an average annual return of 17.22%. Currently, Verisk Analytics has a market capitalization of $44.41 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,103.04 today based on a price of $317.51 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749054696_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

Here's How Much You Would Have Made Owning Verisk Analytics Stock In The Last 15 Years

HOTH

Hoth Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 25%

Acting FAA Administrator Rocheleau Reportedly Says He is Not Currently Thinking About Revisiting Boeing's 38 Plane Per Month 737 Max Production Cap

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1535527/000153552725000019/crwd-20250430.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1535527/000153552725000019/crwd-20250430.htm</a>

CRWD

Crowdstrike Has Received Requests From DOJ, SEC for Information Relating to the Company's Recognition of Revenue and Reporting of ARR for Transactions With Certain Customers, the July 19 Incident and Related Matters

Thor Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) shares are trading higher on Wednesday after the company reported third-quarter EPS of $2.53 <a href="https://www.benzinga.com/earnings">beating the street consensus of $1.83</a>.
Quarterly sales of&nbsp;$2.89 billion, up 3.3%&nbsp;year over year (Y/Y), outpaced the analyst <a href="https://www.benzinga.com/pressreleases/25/06/g45766242/thor-industries-announces-third-quarter-fiscal-2025-results" target="_blank" rel="noreferrer noopener">consensus estimate of&nbsp;$2.48 billion</a>.
Gross profit margin in the quarter under review expanded by 20 basis points year over year to&nbsp;15.3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a>
Adjusted EBITDA increased 7.9%&nbsp;Y/Y to&nbsp;$254.8 million in the quarter.
North American Towable Recreational Vehicle (RV) net sales increased&nbsp;9.1% Y/Y, while North American Motorized RV net sales rose 3.1%&nbsp;Y/Y in the quarter.
North American Towable RV net sales benefitted from 5.5% higher unit shipments and a 3.6% increase in net price per unit. 
Gross profit margin improved 200 basis points to 14.9%, attributed to higher sales, less discounting, better warranty costs, and ongoing savings.
North American Motorized RV net sales increased due to a 10.9% rise in unit shipments (partly from promotions), though a 7.8% decrease in net price per unit (due to product mix shift and higher discounting) partially offset this. 
Gross profit margin fell to 10.5% from 11.1%, primarily owing to increased sales discounting.
As of April 30, the order backlog for North American Towable RV stood at $634.3 million (-14.4%) and North American Motorized RV came in at $883.7 million (-4.5%).
European RV net sales decreased&nbsp;5.1% Y/Y&nbsp;for the&nbsp;quarter, led by a&nbsp;12.2%&nbsp;decrease in unit shipments, which was offset in part by a&nbsp;7.1% Y/Y&nbsp;increase in the overall net price per unit.&nbsp;
European RV net sales fell due to a 12.2% drop in unit shipments, partially offset by a 7.1% increase in net price per unit. The price increase included a 6.8% rise from product mix and pricing changes, plus a 0.3% benefit from foreign currency exchange rates.
European RV gross profit margin contracted 130 basis points to 16.2% on increased sales discounting.
As of&nbsp;April 30, the order backlog for European RV came in at $1.34 billion (-30.6%).
The company exited the quarter with cash and cash equivalents worth&nbsp;$508.3 million, with net inventories worth&nbsp;$1.35 billion. Long-term debt (net) at the end of the quarter stood at $1.01 billion.
Todd Woelfer, senior VP and COO, said, &#8221;As we anticipated and messaged at the beginning of our fiscal year, our North American Motorized and European segments have both seen year-over-year declines in gross margin but still achieved resilient results considering the challenging environments facing those segments.&#8221; 
&#8221;While our consolidated margin this quarter was unfavorably impacted by actions we took to deepen our partnerships with key dealers, strategically, deepening these key relationships is vital to our long-term market position and these decisions favorably position THOR for the future as we look ahead,&#8221;
Thor Industries reaffirmed its FY25 EPS guidance of $3.30 to $4.00 compared <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to analyst estimates of $3.59</a>.
The company also maintained its FY25 sales guidance at $9.00 billion to $9.50 billion versus the <a target="_blank" href="https://www.benzinga.com//node/44139488" rel="noreferrer noopener">analyst estimate of $9.25 billion</a>.
Bob Martin, president and CEO, added, &#8221;Our financial guidance assumed a stronger second half of our fiscal year, and our fiscal third quarter performance reflects the value of our strategies in the currently difficult market.&#8221;
&#8221;We expect the fourth quarter of our fiscal 2025 and the first quarter of our fiscal 2026 to be challenging. The current economic uncertainty has led to downward pressure on consumer confidence and has negatively impacted retail pull-through. We believe that upon the resolution of this uncertainty, we will see improved consumer confidence and the return of a strong retail environment,&#8221; he added.
Year-to-date, the stock has declined around 11%. The short float for Thor Industries is 18.33%, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Price Action: THO shares are trading higher by 3.44% to $85.25 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45765484/dow-futures-edge-higher-after-two-days-of-gains-expert-says-trump-tariffs-distorting-pretty-much-everything" target="_blank" rel="noreferrer noopener">Dow Futures Edge Higher After Two Days Of Gains: Expert Says Trump Tariffs &#8216;Distorting Pretty Much Everything&#8217;</a></li>
</ul>
Image by Michael Gordon via Shutterstock

Earnings

Guidance

Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook

Analyst Ratings

Live On CNBC, Jim Lebenthal Announced Trimmed Microsoft

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang highlighted the company's role in helping boost the new features of <a href="https://www.benzinga.com/general/gaming/25/04/44609298/nintendo-switch-2-price-release-date-specs-new-games-revealed">the highly anticipated</a><a href="https://www.benzinga.com/general/gaming/25/04/44609298/nintendo-switch-2-price-release-date-specs-new-games-revealed"> </a>Nintendo Switch 2 gaming console from Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) in a recent video.
What Happened: Nintendo stock has soared in 2025 ahead of the June 5 release of the Switch 2, a handheld video game console that follows up the highly successful Nintendo Switch released in 2017.
"It brings together three breakthroughs: the most advanced graphics ever in a mobile device, full hardware ray tracing, high dynamic range for brighter highlights and deeper shadows and an architecture that supports backward compatibility," Huang said in a video <a href="https://x.com/NintendoAmerica/status/1929886108113932624">shared </a>by Nintendo.
Huang said the Nvidia chip inside the Switch 2 is "unlike anything we've built before," as <a href="https://www.cnbc.com/amp/2025/06/03/nintendo-switch-2-ai-nvidia.html">reported</a> by CNBC.
The Nvidia CEO said the Switch 2 has dedicated artificial intelligence processors that will help to "sharpen, animate and enhance gameplay in real time."
"Switch 2 is more than a new console. It's a new chapter worthy of Iwata-san's vision."
Huang's comments paid tribute to former Nintendo CEO Satoru Iwata, who passed away in 2015 before the first Switch was released. Iwata worked on the concept of the original Switch.
Read Also:<a href="https://www.benzinga.com/news/education/25/05/45701924/jensen-huang-founded-nvidia-at-a-dennys-now-hes-worth-600x-more-than-the-restaurant-chain"> Jensen Huang Founded Nvidia At A Denny&#8217;s, Now He&#8217;s Worth 600x More Than The Restaurant Chain</a>
Why It's Important: The Nintendo Switch 2 will be released on June 5 and comes with a suggested retail price of $449.99 for the U.S. market.
The console is the first from Nintendo in eight years and comes with new features that have gamers excited to get their hands on devices as soon as possible.
Nintendo expects to sell 15 million Switch 2 consoles in the current fiscal year, as <a href="https://www.cnbc.com/video/2025/05/08/nintendo-expects-to-sell-15-million-units-of-the-switch-2.html">reported </a>by CNBC. The console will likely help boost Nintendo's financials and could send shares higher with strong early sales figures and high demand.
Nvidia stock could also get a small boost. While the Gaming &amp; AI PC division for Nvidia is smaller than its Data Center business, the segment saw first-quarter revenue of $3.8 billion, which was up 42% year-over-year.
The gaming segment saw revenue jump 48% quarter-over-quarter in the first quarter, the highest sequential growth of any Nvidia segment.
Nvidia highlighted its products being used for the Nintendo Switch 2 during the earnings report. The big question will be how much of the revenue is already baked into the segment versus potential upside from more devices sold in future quarters or demand quickly outpacing supply.
Price Action: Nvidia stock is down 0.24% at $140.89 on Wednesday versus a 52-week trading range of $86.63 to $153.13. Nvidia stock is up 2.1% year-to-date in 2025.
Nintendo stock is up 2.40% at $20.93 on Wednesday versus a 52-week trading range of $11.36 to $22.08. Nintendo stock is up 42.9% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong">Nvidia Q1 Highlights: China Export Ban Hits Results But Jensen Huang Says Demand &#8216;Incredibly Strong&#8217;</a></li>
</ul>
Photo: Shutterstock

Gaming

Long Ideas

Management

NTDOY

Jensen Huang Says Nintendo Switch 2 Has AI Processors To Enhance Gameplay: 'Unlike Anything We've Built Before'

JPMorgan analyst Mark R Murphy <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings" target="_blank" rel="noreferrer noopener">reiterated an Overweight</a> rating on Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a price target of $225 on Wednesday.
Murphy attended Snowflake&#8217;s Investor Day presentation in San Francisco, in conjunction with its annual Summit conference. Snowflake&#8217;s Investor Day presentation primarily focuses on its product and technology roadmap as it lays out an expansive strategic vision for the data cloud in the era of AI, the analyst said.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45623498/snowflakes-ai-driven-insights-to-power-la28-olympic-and-paralympic-games" rel="noreferrer noopener">Snowflake&#8217;s AI-Driven Insights To Power LA28 Olympic And Paralympic Games</a>
A financial section was absent from the Investor Day presentation, an understandable dynamic as Snowflake continues its process to select a new CFO after current CFO Mike Scarpelli&#8216;s planned retirement, he said.
Despite the lack of explicit financial guidance or macro-demand update, Murphy noted Snowflake is striking a confident tone overall as it begins to realize benefits from the product, go-to-market (GTM), and other operational initiatives it has undertaken or accelerated since Sridhar Ramaswamy was elevated to CEO in February 2024.
Net-net, the analyst came away incrementally positive following the Investor Day and the relatively upbeat nature of his conversations thus far with partners and customers regarding Snowflake.
Recently-appointed CRO Mike Gannon provided an overview of Snowflake&#8217;s Go-To-Market organization and stated that Snowflake hired over 500 sales and marketing folks in the first quarter. While the 500 additional S&amp;M heads is a gross figure, Murphy noted the hiring scale is notable, particularly as hiring activity across many other software companies has been relatively more muted, and likely reflects the opportunity Snowflake is seeing in the market.
Snowflake discussed ongoing industry adoption of the Iceberg data formats, noting that open data table formats like Iceberg make it easier for customers to switch between different data processing engines. As a result, the analyst noted that Snowflake said that customers will move toward the data platforms that offer the most value.
For Snowflake, Iceberg is experiencing a dynamic wherein the tailwinds and opportunity it provides &#8220;far exceed and outpace the potential headwinds,&#8221; he said.
When asked about its view on more and more SaaS companies moving into the data layer, Murphy said that Snowflake suggested that this move is driven by AI as the rise of Agents is potentially impacting the traditional SaaS model.
However, Snowflake noted that it has a bidirectional data-sharing dynamic with many leading SaaS companies and that the relationships are mutually beneficial.
Snowflake built on its vision of the AI Data Cloud through a series of product unveilings. These announcements included Openflow, Gen2, Adaptive Compute, Intelligence, Snowflake Data Science Agent, and Cortex AISQL.
Murphy is encouraged by Snowflake&#8217;s slate of new products and the recent increased pace of innovation.
In the long term, the analyst noted that Snowflake is benefiting from demonstrable secular tailwinds, supported both qualitatively and quantitatively by his CIO Survey and partner checks. He continues to be impressed by the company&#8217;s accelerated pace of product innovation, including around AI/ML. 
Murphy noted favorable competitive positioning in the longer term as the data layer increasingly gains control over AI.
The analyst projected second-quarter revenue of $1.08 billion and adjusted EPS of $0.25.
Price Action: SNOW stock is trading higher by 1% to $211.24 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45755544/rising-ai-analytics-budgets-could-lift-microsoft-snowflake-datadog" target="_blank" rel="noreferrer noopener">Rising AI, Analytics Budgets Could Lift Microsoft, Snowflake, Datadog</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

SNOW

Snowflake Just Hired 500 Sellers—Is This The Start Of A Full-Scale AI Land Grab?

CSCO

Live On CNBC, Jim Lebenthal Announced Bought More Cisco; Bought More Qualcomm

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 5 years by 16.18% on an annualized basis producing an average annual return of 29.4%. Currently, Amphenol has a market capitalization of $111.72 billion. 
Buying $100 In APH: If an investor had bought $100 of APH stock 5 years ago, it would be worth $354.53 today based on a price of $92.25 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749053712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Amphenol 5 Years Ago Would Be Worth This Much Today

On June 3, 2025 Enterprise Products Partners Received Notice From The U.S. Department Of Commerce's Bureau Of Industry And Security Of BIS's Intent To Deny Emergency Authorization Requests With Regard To Three Proposed Cargoes Of Ethane To China, Totaling Approximately 2.2M Barrels

The Magnificent Seven did not disappoint in May, posting a <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45722678/magnificent-seven-closed-a-blockbuster-may-added-nearly-2-trillion-in-market-value">record-breaking $1.75 trillion in collective market cap gain</a>, their strongest combined performance in years. 
The center of the mania: the Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), which saw its best monthly performance since inception, powered by an AI-driven, earnings-supported technology surge.
But with valuations sky-high and Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in reverse gear, is this still a time to buy, or has the market become too magnificent for its own good?
Benzinga spoke to David Mazza, <a href="https://www.benzinga.com/topic/david-mazza">CEO of Roundhill Investments</a>, to discuss the factors behind MAGS&#8217; &#8220;best month since inception&#8221; and whether the <a href="https://www.benzinga.com/etfs">ETF&#8217;s star status</a> still shines through in changing macro winds.
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/45774924/apple-stock-too-pricey-analyst-warns-of-rising-competition-tariff-risks-favors-2-tech-giants">Apple Stock Too Pricey? Analyst Warns Of Rising Competition, Tariff Risks, Favors 2 Tech Giants</a>
<h2 class="wp-block-heading">Broad-Based Gains, Not Just A One-Stock Show</h2>
&#8220;What stood out was the breadth of the rally,&#8221; Mazza said in an interview with Benzinga. &#8220;Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) led with a 24% gain, but Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) also posted double-digit gains, signaling a broad-based resurgence in the mega caps.&#8221;
The tailwind, Mazza said, was fueled by easing trade tensions and healthy earnings, especially in AI and cloud. &#8220;While we anticipated strength from these companies, the magnitude and breadth of the rally exceeded expectations.&#8221;
Nvidia contributed alone with $639 billion worth of market cap, while Tesla and Meta were not far behind. Microsoft added $484 billion, Amazon increased by $219 billion, and Alphabet added $152 billion.
Also Read:<a href="https://www.benzinga.com/etfs/new-etfs/25/06/45774136/wedbush-launches-ai-revolution-etf-backed-by-dan-ives-proprietary-tech-picks"> Wedbush Launches AI Revolution ETF Backed By Dan Ives&#8217; Proprietary Tech Picks</a>
<h2 class="wp-block-heading">Apple Lags Behind, But MAGS Remains Firm</h2>
The sole laggard among the gang was Apple, which dropped 6%, erasing $192 billion in market capitalization and significantly underperforming the S&amp;P 500. Nevertheless, MAGS&#8217; equal-weighting approach prevented the decline from derailing the ETF&#8217;s performance.
&#8220;Apple&#8217;s underperformance, influenced by trade tensions and delayed AI initiatives, presents a potential buying opportunity,&#8221; Mazza said, highlighting the stock&#8217;s solid ecosystem and diversified manufacturing strategy.
<h2 class="wp-block-heading">Why The Magnificent Seven Still Matter</h2>
More than mere tech giants, Mazza views the Magnificent Seven as critical plumbing to the economy of today. These firms drive everything from cloud computing to e-commerce, he said. &#8220;MAGS focuses exclusively on these companies, providing targeted exposure to the core drivers of modern economic growth.&#8221;
As opposed to the broad tech ETFs that encompass legacy or cyclical names, MAGS is laser-like. And while volatility clouds traditional sectors, some analysts, including Goldman Sachs, have referred to these mega-caps as a &#8220;defensive growth proxy.&#8221;
Mazza does too.
&#8220;These companies combine strong growth prospects with resilient business models, making them attractive during uncertain times. Goldman Sachs&#8217; characterization of them as a &#8216;defensive growth proxy&#8217; aligns with our view,&#8221; he agreed.
<h2 class="wp-block-heading">The Question Of Valuation: Bubble Or Justified?</h2>
With the Magnificent Seven's forward P/E ratio now pushing 27.4x, the ghost of the dot-com bubble inevitably enters the chat. But Mazza sees a key difference.
"While the group&#8217;s median forward P/E ratio has risen to around 27x, it&#8217;s important to note that these valuations are supported by substantial earnings growth and strong fundamentals," he said. "Unlike the dot-com era, these companies are profitable and generate significant cash flow," Mazza noted. Nvidia, for example, posted a 69% YoY revenue jump last quarter.
<h2 class="wp-block-heading">Earnings Outlook And The AI Edge</h2>
Mazza is also optimistic about earnings, citing the group&#8217;s leading position in AI, cloud, and digital services. &#8220;Given their central roles in AI, cloud computing, and digital services, we anticipate continued earnings momentum as demand for these technologies persists and expands across various sectors.&#8221;
While MAGS provides exposure to high-cap AI adopters, Roundhill also has the CHAT ETF available for investors wanting more focused plays on Generative AI.
&#8220;We view AI as a transformative force with long-term implications. The companies within MAGS are not only early adopters, but also key enablers of AI technologies,&#8221; Mazza clarified. 
<h2 class="wp-block-heading">What&#8217;s Next For MAGS?</h2>
Even with the monster rally, Mazza dampens expectations for the remainder of 2025.
&#8220;We don't expect a repeat of the massive gains we saw in the past year, but that doesn't mean the story is over,&#8221; he conceded. &#8220;If earnings growth remains solid and rate expectations stay in check, MAGS could still deliver compelling returns, just more measured than the blockbuster runs we&#8217;ve recently witnessed.&#8221;
With the market still characterized by uncertainty, Mazza feels that Magnificent Seven&#8217;s growth, quality, and macro sensitivity are an elusive combination.
These companies are essential to enterprise and consumer activity,&#8221; he said. &#8220;And MAGS is built to give investors direct exposure to that durability.&#8221;
<h2 class="wp-block-heading">Bottom Line</h2>
May might have been magnificent, but the future of MAGS will be more measured, not muted. For those who want a high-conviction wager on AI, cloud, and the core players in the digital economy, Mazza makes the case the ETF is a singularly focused yet compelling entry point.
After all, in a world short on clarity, the Magnificent Seven might just be the market&#8217;s most down-to-earth stars.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45771855/vistashares-unleashes-wild-a-2x-leveraged-etf-powered-by-animal-spirits-and-market-momentum">VistaShares Unleashes WILD, A 2x Leveraged ETF Powered By Animal Spirits And Market Momentum</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

Exclusives

AMZN

GOOGL

MAGS

TSLA

David Mazza On MAGS' Magnificent May: 'The Breadth Of The Rally Stood Out'

Loop Capital analyst Mark Schappel maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $220 to $245.

Loop Capital Maintains Buy on Snowflake, Raises Price Target to $245

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) re-elected all current directors on Wednesday. The board authorized the payment of a cash dividend of $2.21 per share, up from the <a href="https://www.unitedhealthgroup.com/investors/stock.html" target="_blank" rel="noopener">prior</a> dividend of $2.10, to be paid June 24 to common stock shareholders of record as of the close of <a href="https://www.benzinga.com/pressreleases/25/06/b45766386/unitedhealth-group-updates-on-annual-shareholder-meeting-board-actions" target="_blank" rel="noreferrer noopener">business June 16</a>.
In May, UnitedHealth Group&#8217;s CEO&nbsp;, Andrew Witty,&nbsp;resigned for personal reasons. Stephen Hemsley, who previously held the CEO title from 2006 to 2017,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">succeeded him</a>. The company also suspended its 2025 outlook.
In an SEC filing on Wednesday, UnitedHealth <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/731766/000073176625000154/unh-20250602.htm" target="_blank" rel="noreferrer noopener">said</a> it canceled the performance-based restricted stock units granted to Witty,
Year to date, UnitedHealth Group&#8217;s stock has plunged almost 40%, with the majority coming after the disappointing fourth-<a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" target="_blank" rel="noreferrer noopener">quarter 2024 earnings</a>.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45687019/unh-stock-broken-contrarian-traders-eyeball-recovery" target="_blank" rel="noreferrer noopener">Options Corner: UnitedHealth May Be Broken But Contrarian Traders Eyeball A Recovery</a>
UnitedHealth&#8217;s aggressive growth strategy under Witty exposed the healthcare giant to mounting regulatory scrutiny, soaring costs, and a <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">shifting Medicare landscape</a>.
UnitedHealth plans to enlist independent experts to examine its Medicare billing practices, which were criticized following a Wall Street Journal <a href="https://www.benzinga.com/general/health-care/25/05/45443695/why-is-unitedhealth-stock-trading-lower-on-thursday" target="_blank" rel="noreferrer noopener">investigation last year</a>.
Hemsley is stepping forward to acknowledge the fallout and chart a new course, promising a comprehensive review of some of the company's most controversial practices.
The Wall Street Journal noted in its report on the company's annual shareholder meeting on Monday that Hemsley apologized for UnitedHealth's recent performance and cited a need to rethink many internal processes.
He said the company has factored recent results into its 2025 Medicare bids and emphasized a "fresh perspective" on issues that have drawn widespread criticism.
Under Witty, UnitedHealth scaled up its dominance in Medicare Advantage, the privately managed alternative to traditional Medicare.
Former employees said UnitedHealth's profit margins on Medicare enrollees were roughly double those of traditional Medicare insurers.
That advantage stemmed partly from federal rules that limit the premium revenue pure insurers can keep. Additionally, the government pays more for patients with certain chronic diagnoses—a system UnitedHealth capitalized on by gathering such data at high rates.
However, changes announced by the Medicare agency in 2023 altered the rules, reducing or eliminating extra payments for many diagnoses. The changes, phased in starting this year, were expected to have a major financial impact.
An internal analysis <a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-ceo-andrew-witty-medicare-dde1964c" rel="noreferrer noopener">viewed</a> by the WSJ indicated the new rules would significantly reduce the number of reimbursable chronic diagnoses for nearly 900,000 patients.
Despite this, UnitedHealth continued betting on Medicare growth for 2025, even in high-risk patient segments, while rivals pulled back following profit hits in 2024 tied to rising costs.
Hemsley said the company would also examine its pharmacy services and managed care policies, including prior authorization—a process that has faced growing criticism from physicians and patients.
Price Action: UNH stock was flat at $301.29 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" target="_blank" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a></li>
</ul>
Photo: Piotr Swat / Shutterstock.com

Dividends

UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices

Truist Securities analyst Scot Ciccarelli maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Hold and raises the price target from $93 to $112.

Truist Securities Maintains Hold on Dollar General, Raises Price Target to $112

Truist Securities analyst Joel Fishbein reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $450 to $500.

Truist Securities Reiterates Buy on CrowdStrike Holdings, Raises Price Target to $500

워싱턴이 우호적이지 않은 국가들에 대한 반도체 칩 수출 규제를 강화함에 따라 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)는 반도체 <a href="https://www.benzinga.com/topic/semiconductors" target="_blank" rel="noopener">산업의 글로벌 환경</a>을 혼란에 빠뜨릴 수 있는 지정학적 권력 이동의 한가운데에 있다.
월요일에 공유된 블룸버그의 보고서에 따르면, 바이든 행정부는 <a href="https://www.benzinga.com/government/regulations/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report" target="_blank" rel="noopener">고급 반도체를 겨냥한</a> 새로운 수출 규정을 곧 발표할 예정이다.
이번 주 금요일 발표될 새로운 조치는 고성능 컴퓨팅 칩에 대한 접근을 제한함으로써 중국의 기술 및 군사 발전을 저지하려는 미국의 전략적 노력을 강화한다.
<h3 class="wp-block-heading">새로운 AI 수출 프레임워크: 동맹과 적</h3>
이 규정은 반도체 수출에 대한 3단계 구조를 만들고, 주요 미국 동맹국, 중립 국가 및 제한 국가에 대한 접근 수준을 강조할 것으로 보인다.
중국은 러시아, 이란 및 베네수엘라와 함께 가장 엄격한 단계에 포함될 것으로 예상된다.
이 단계별 프레임워크는 제한 국가들의 특정 기업들이 미국의 보안 프로토콜과 인권 기준에 동의하면 국가적 한계를 우회할 수 있도록 한다.
이러한 기관들은 검증된 최종 사용자들로 지정되어 칩 구매 한도가 높아지며, 이는 전 세계적으로 안전한 인공지능(AI) 개발을 장려하기 위한 조치이다.
이번 조치는 이미 2022년 10월에 시행된 광범위한 수출 제한을 확장한 것으로, 당시에는 엔비디아의 호퍼(Hopper) GPU와 같은 고급 AI 칩의 판매가 제한되었다.
이전 규정은 미국 기업들과 개인들이 중국 칩 개발을 지원하는 것을 명시적인 정부 승인 없이 금지했다.
<h3 class="wp-block-heading">엔비디아와 AMD에 대한 집중 조사</h3>
엔비디아의 A800 및 H800 칩은 이전 규정을 준수하기 위해 개발되었지만, 새로운 제한에 적용될 경우 AI 거인의 향후 매출에 타격을 줄 수 있다.
데이터 회사인 팩트셋(FactSet)에 따르면, 중국은 엔비디아의 매출에서 약 16%를 차지하며, 이는 회사의 두 번째로 큰 시장이다. 이는 2022년 수출 제한 이전의 25%에서 감소한 수치이다.
2023년에는 AMD가 중국(홍콩 포함)에서 약 34억 달러의 매출을 올렸으며, 이는 회사의 총 매출 227억 달러의 15%를 차지한다.
<h3 class="wp-block-heading">엔비디아와 AMD에 관련된 주요 ETF</h3>
엔비디아와 AMD에 크게 노출된 여러 ETF가 영향을 받을 수 있다:
엔비디아를 보유한 주요 ETF (보유 비율):
<ul>
<li>ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>): 34.96%</li>
<li>Strive U.S. Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOC#NASDAQ">SHOC</a>): 21.10%</li>
<li>YieldMax Target 12 Semiconductor Option (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXY#NASDAQ">SOXY</a>): 20.50%</li>
<li>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>): 20.21%</li>
<li>VanEck Fabless Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMHX#NASDAQ">SMHX</a>) – 20.11%</li>
</ul>
AMD를 보유한 주요 ETF (보유 비율):
<ul>
<li>VanEck Video Gaming and Esports ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPO#NASDAQ">ESPO</a>): 8.01%</li>
<li>iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>): 7.12%</li>
<li>AOT Growth and Innovation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOTG#NASDAQ">AOTG</a>): 7.07%</li>
<li>Invesco PHLX Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXQ#NASDAQ">SOXQ</a>): 7.04%</li>
<li>REX FANG &amp; Innovation Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEPI#NASDAQ">FEPI</a>): 6.95%</li>
</ul>
다음 읽어보기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EA%B3%A8%EB%93%9C%EB%A7%8C%EC%82%AD%EC%8A%A4-%EC%9D%B8%ED%94%8C%EB%A0%88%EC%9D%B4%EC%85%98%EA%B3%BC-%ED%8A%B8%EB%9F%BC%ED%94%84-%EC%A0%95%EC%B1%85-%EB%B6%88%ED%99%95%EC%8B%A4%EC%84%B1-%EC%86%8D/" target="_blank" rel="noopener">골드만삭스, 인플레이션 및 트럼프 정책으로 인한 불확실성으로 시장 조정 리스크 경고</a></li>
</ul>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

세계 최대 칩 제조사 중 두 곳인 ARM 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)와 퀄컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)이 이번 주 <a href="https://www.benzinga.com/topic/intellectual-property" target="_blank" rel="noopener">지적재산권에 대한 의견</a> 차이로 법정에서 충돌할 예정이다.
무슨 일 있었나: 블룸버그 통신은 12월 16일 월요일, 델라웨어의 연방 배심원단 앞에서 ARM 홀딩스와 퀄컴의 법적 공방이 시작되었다고 <a href="https://www.bloomberg.com/news/articles/2024-12-16/arm-qualcomm-contract-fight-threatens-to-upend-chip-industry?sref=TBDibEcD">보도했다.</a>
2021년 퀄컴이 칩 스타트업인 <a href="https://www.benzinga.com/government/21/01/19148004/qualcomm-to-buy-startup-nuvia-in-1-4b-deal-what-investors-need-to-know" target="_blank" rel="noopener">누비아(NUVIA)를 14억 달러에 인수했는데,</a> 불과 2년 전에 ARM 홀딩스는 누비아에 라이선스를 부여했고, 결국 퀄컴이 그 자산을 물려받게 되었다.
영국에 본사를 두고 있으며 소프트뱅크 그룹이 대주주로 있는 ARM 홀딩스는 누비아 거래에 재협상이 필요하다고 주장하고 있다. 또한 거래가 성사된 후 퀄컴이 받은 특정 칩 설계를 폐기할 것을 요구하고 있다.
반면에 퀄컴은 법원 문서에서 ARM 홀딩스와 자체 라이선스 계약을 체결했다고 <a href="https://semianalysis.com/wp-content/uploads/files/71776a9c-ee79-4c5c-947b-f7e98cf40bcc.pdf" target="_blank" rel="noopener">주장하고 있다</a>. "퀄컴은 누비아가 ARM 홀딩스와 별도의 계약에 따라 라이선스를 받은 것과 동일한 지적재산에 대해 라이선스를 가지고 있고 비용을 지불했다.&#8221;
<h3>주목해야 할 ETF</h3>
<a href=""https://pro.benzinga.com/"">Benzinga Pro</a>에 따르면 반도체 ETF는 월요일(16일) 상승 마감했다.
<ul>
<li>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) 0.56% 상승</li>
<li>Invesco PHLX Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXQ#NASDAQ">SOXQ</a>) 0.49% 상승</li>
<li>Columbia Semiconductor and Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMI#NYSE">SEMI</a>) 2.75% 상승</li>
<li>Direxion Daily Semiconductor Bull 3X Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>) 5.88% 상승</li>
</ul>
왜 중요한가: 이번 ARM 홀딩스 대 퀄컴 사건(Arm v. Qualcomm, 22-cv-01146, US District Court, District of Delaware (Wilmington))에서는 르네 하스 ARM 홀딩스 CEO와 크리스티아노 아몬 퀄컴 CEO 두 사람이 모두 증언할 가능성이 높다.
두 회사가 관련된 M&amp;A 계약이 법적 문제를 일으킨 것은 이번이 처음이 아니다. 2020년에 엔비디아는 ARM 홀딩스를 400억 달러에 인수하려고 시도했고, 이로 인해 샌디에이고에 본사를 둔 퀄컴과 다른 기술 기업들이 패닉에 빠졌다.
규제 당국은 2022년 연방거래위원회가 합병을 막기 위해 엔비디아를 고소하면서 거래를 무산시켰다. 또한 ARM 홀딩스는 영국 당국으로부터 상당한 규제 압력에 직면했다.
현재 ARM 홀딩스는 약 15억 달러에 달하는 퀄컴의 라이선스를 빼내려고 위협하고 있다.
하지만 퀄컴도 쉽게 포기하지 않을 것으로 보인다. 2019년 4월에 <a href="https://www.apple.com/newsroom/2019/04/qualcomm-and-apple-agree-to-drop-all-litigation/" target="_blank" rel="noopener">합의한</a> 애플과의 라이선스 분쟁을 떠올려보면 그렇다.
전망: 애널리스트들은 결국 양사가 합의할 것으로 예상하며, 아마도 퀄컴이 ARM 홀딩스의 기술에 접근하기 위해 더 많은 비용을 지불할 것으로 예상한다. 소송 절차는 12월 20일(금)까지 마무리될 것으로 보인다.
문제가 된 칩은 대부분의 주류 기기에 탑재되어 있으며, 법적 분쟁은 기술 산업에 광범위한 영향을 미칠 수 있다는 점에 주목할 필요가 있다.
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

인공 지능의 추진에 힘입어 반도체 기업들의 주가가 고공행진을 이어가고 있는 가운데, 현재 미국 칩 제조 산업은 <a href="https://www.benzinga.com/markets/equities/24/06/39213777/nvidia-propels-semiconductor-industry-to-5-5-trillion-valuation-beginning-of-bigger-boom-says-an" target="_blank" rel="noopener">총 가치가 6조 3천억 달러</a>에 달한다.
Invesco PHLX 반도체 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXQ#NYSE">SOXQ</a>)가 반영하는 필라델피아 반도체 지수(PHLX Semiconductor Sector Index)는 이번 주에 6% 상승할 것으로 예상되어 두 달 만에 가장 강력한 실적을 기록하고 사상 최고 수준을 달성했다.
2023년 10월 말 이후 이 지수는 78% 급등했으며, 광범위한 칩 산업은 2022년 10월 최저치보다 무려 169% 상승했다.
이와는 대조적으로 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>가 추적하는 광범위한 기술 부문은 2023년 10월 최저치보다 39%, 2022년 10월 이후 88% 상승했다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-389619" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14143405/SOXQ_2024-06-14_20-32-29_7bf4b-1024x500.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14143405/SOXQ_2024-06-14_20-32-29_7bf4b-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14143405/SOXQ_2024-06-14_20-32-29_7bf4b-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14143405/SOXQ_2024-06-14_20-32-29_7bf4b-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14143405/SOXQ_2024-06-14_20-32-29_7bf4b-1536x750.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14143405/SOXQ_2024-06-14_20-32-29_7bf4b.png 1920w" alt="" width="1024" height="500" /></figure>
<h3 class="wp-block-heading">엔비디아의 지배력이 계속될 조짐</h3>
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 최근 미국 반도체 산업 전체 가치의 거의 절반에 해당하는 3조 달러의 가치 평가를 넘어섰다. 현재 이 회사는 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 및 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) 등 거대 기업들과 경쟁하며 세계 최대 기업 타이틀을 놓고 경쟁하고 있다.
LPL 파이낸셜의 포트폴리오 전략가인 조지 스미스(George Smith)는 "초기 AI 분야에서 엔비디아의 지배력을 고려할 때 엔비디아가 마이크로소프트를 능가하여 세계에서 가장 가치 있는 회사가 되는 것은 시간 문제일 수 있다"라고 말했다.
이 전문가에 따르면 기술 관련 ETF가 다음 재조정 동안 이 칩 제조업체에 대한 노출을 늘려야 하므로 엔비디아의 랠리가 계속될 가능성이 높다.
<h3 class="wp-block-heading">이번 주 가장 성공적인 칩 제조업체</h3>
놀랍게도, 이번 주 반도체 주식 가운데 가장 많이 오른 기업은 엔비디아가 아니다.
이 주에 이 선도적인 칩 제조업체의 주가가 9.4% 상승한 반면, 다른 6개 반도체 회사들은 엔비디아를 앞지르며 더욱 강력한 상승세를 보였다.
브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)은 쿠퍼티노에 본사를 둔 아이폰 제조업체가 WWDC 2024에서 새로운 AI 이니셔티브를 발표한 이후 예상보다 강한 실적과 최고 고객인 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)의 개선된 AI 관련 수요 전망에 힘입어 이번 주에 22% 급등했다. 이는 2009년 이 회사가 상장된 이후 최고의 주이다.
영국의 컴퓨터 프로세서 및 소프트웨어 설계 회사인 Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)는 14% 상승하며 6주 연속 상승세를 기록하며 칩 제조업체들 중 두 번째로 좋은 성적을 거두었다. Arm은 6월 24일부터 나스닥 100 지수에 편입될 예정이다.
코보(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)는 이번 주 주가가 13% 상승하며 바짝 뒤따랐다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>시가총액</td>
<td>주가 변동율 (5일)</td>
</tr>
<tr>
<td>브로드컴</td>
<td>8036.7억 달러</td>
<td>22.74%</td>
</tr>
<tr>
<td>Arm 홀딩스</td>
<td>1,619억 달러</td>
<td>13.95%</td>
</tr>
<tr>
<td>코보</td>
<td>107.8억 달러</td>
<td>13.25%</td>
</tr>
<tr>
<td>액셀리스 테크롤로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>)</td>
<td>45.2억 달러</td>
<td>11.08%</td>
</tr>
<tr>
<td>유니버셜 디스플레이 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NASDAQ">OLED</a>)</td>
<td>95.3억 달러</td>
<td>9.70%</td>
</tr>
<tr>
<td>엔비디아</td>
<td>3조 2,508.3억 달러</td>
<td>9.42%</td>
</tr>
<tr>
<td>노바 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>)</td>
<td>69.6억 달러</td>
<td>9.13%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">ET 기준 6월 14일 오후 2시 13분에 업데이트됨</figcaption></figure>
지금 읽기: <a href="https://www.benzinga.com/markets/equities/24/06/39334146/consumer-sentiment-tumbles-in-june-reaches-7-month-low-high-prices-as-well-as-weakening-incomes-">6월 소비자 심리 7개월 만에 최저 기록, &#8216;물가 상승과 소득 약화&#8217; 우려</a>
사진: 샤터스톡

파이퍼 샌들러(Piper Sandler)의 애널리스트 하쉬 V. 쿠마르(Harsh V. Kumar)는 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)에 대해 <a href="https://www.benzinga.com/quote/AMD/analyst-ratings" target="_blank" rel="noreferrer noopener">195달러의 목표 주가로</a> 비중확대(Overweight) 평가를 재확인했다.
이 분석가는 올해에 AMD에 대한 기대와 특히 MI300 램프 제품의 전망 및 서버 사업에 대한 의견을 업데이트 하였다.
쿠마르는 MI300의 가격 대비 성능 비율이 정말 강력하며 특히 추론 애플리케이션을 중심으로 관심을 끌고 있다고 주장했다. 이러한 애플리케이션에서는 메모리 성능과 관련된 지연 시간이 가장 중요하며 쿠마르는 MI300이 이러한 문제를 해결하도록 구성되었다고 생각했다.
쿠마르는 올해와 2025년의 MI300 목표를 실행할 수 있는 경영진의 능력에 대해 자신감을 표명했다. 쿠마르는 현재 2024년에 40억 달러, 2025 회계연도에 76억 달러의 MI300 수익을 모델로 삼았다.
분석가는 2023년 경기 침체와 그에 따른 조정 이후 서버 CPU 재고가 크게 개선되었다고 지적했다.
그는 가속화된 컴퓨팅으로의 전환에도 불구하고 이 부문이 2024년에 전년 대비 성장할 것이라고 말했다.
그는 AMD가 칩 아키텍처와 고급 패키징을 포함하여 CPU 측면에서 발전을 이루었으며 이는 총 소유 비용(TCO) 이점을 제공한다고 언급했다.
쿠마르에 따르면 AMD는 현재 경쟁업체에서 제공하는 가속기에 비해 TCO 제안을 고려할 때 추론 애플리케이션에 있어 유리한 위치에 있다.
또한 그는 2024년에도 이 부문이 매년 성장할 것이라고 확신하고 있기 때문에 서버 점유율의 모멘텀은 계속될 것으로 보인다.
쿠마르는 또한 AMD가 CPU 서버의 클라우드 측면에서 현재 역할을 하고 있다고 언급했다.
마지막으로 게임 부문은 주로 위험이 제거되었으며 하반기부터 임베디드 부문의 전환을 모색하고 있다.
쿠마르는 1분기 매출과 주당순이익이 각각 541억달러, 57센트로 예측했다.
지난 12개월 동안 AMD 주식은 86% 상승했다. 투자자들은 IShares 반도체 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>)와 Invesco PHLX 반도체 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXQ#NASDAQ">SOXQ</a>)를 통해 AMD에 노출을 얻을 수 있다.
주가 움직임: 금요일 AMD 주식은 2.77% 상승한 170.42달러로 마감했다.
최종 사용일 2022년 02월 14일

AMD의 MI300 칩은 힘을 얻으며, 분석가들은 강력한 성장과 서버 시장에서의 성공을 전망

Comments

Invesco PHLX Semiconductor ETF

뉴스

에 대한 최신 뉴스 Invesco PHLX Semiconductor ETF (NASDAQ:SOXQ)

목요일, 1월 09, 2025

화요일, 12월 17, 2024

금요일, 6월 14, 2024

토요일, 4월 06, 2024

뉴스

파트너 / 기고자

벤징가 글로벌